AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Mucopolysaccharidosis Type II (Hunter Syndrome)

Recent research efforts aimed at curing Mucopolysaccharidosis Type II (Hunter Syndrome).

Last updated

Mucopolysaccharidosis Type II (Hunter Syndrome)

Overview

Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked lysosomal storage disorder caused by harmful variants in the IDS gene. The resulting shortage of the enzyme iduronate-2-sulfatase (I2S) allows complex sugars called glycosaminoglycans (GAGs), including heparan sulfate, to build up inside cells and damage the brain, airways, heart, bones, joints, liver, and other tissues. It affects almost exclusively boys, although disease severity varies widely. In the neuronopathic form, progressive cognitive decline alongside cardiorespiratory disease commonly leads to death in childhood or adolescence; people with attenuated disease can survive well into adulthood. GeneReviews: Mucopolysaccharidosis Type II

The long-standing standard of care has been weekly intravenous enzyme-replacement therapy (ERT) with idursulfase, plus coordinated respiratory, cardiac, orthopedic, hearing, developmental, and surgical care. Idursulfase helps treat body-wide manifestations but does not cross the blood-brain barrier, so it is not expected to halt central nervous system disease. In March 2026, the U.S. Food and Drug Administration (FDA) also granted accelerated approval to tividenofusp alfa-eknm (Avlayah), a brain-penetrant ERT for eligible children before advanced neurologic impairment; this is an important disease-modifying advance, but it is not a genetic cure. GeneReviews: Targeted therapies for MPS II FDA approval of Avlayah

Scope of Recent Research (2020–present)

Research has become notably more active since 2020, driven by the need to reach the brain early enough to prevent irreversible injury. The dominant questions are whether a one-time therapy can supply enough I2S throughout the brain and body, whether biomarkers such as cerebrospinal-fluid heparan sulfate reliably predict developmental benefit, and how to do this safely in very young children. The field is closer than before to durable disease modification, with late-stage gene therapy and an approved brain-penetrant enzyme therapy, but no treatment has yet demonstrated that it permanently corrects all manifestations of MPS II. FDA approval of Avlayah NAVSUNLI regulatory update

Major Breakthroughs and Emerging Therapies

The leading one-time in vivo gene-therapy candidate is clemidsogene lanparvovec-sngl, formerly RGX-121 and now called NAVSUNLI. It uses an adeno-associated virus (AAV) vector to deliver a working IDS gene to cells in the central nervous system, with the goal of creating a long-lasting local source of I2S and enabling “cross-correction,” in which enzyme secreted by treated cells is taken up by neighboring cells. In the company-reported pivotal portion of the CAMPSIITE study, 13 participants had a median 82% reduction in cerebrospinal-fluid heparan sulfate D2S6 at one year, with developmental skills reported as stable or improving relative to baseline function. These are encouraging biomarker and functional observations, but they come from a small, open-label study and have not yet established a cure. CAMPSIITE 12-month data

A separate ex vivo approach modifies a child’s own blood-forming hematopoietic stem cells outside the body with a lentiviral vector carrying IDS. After the cells are returned following transplant conditioning, their blood-cell descendants are intended to continuously make I2S. The Manchester program adds an ApoEII-tagged form of the enzyme designed to improve movement across the blood-brain barrier. Preclinical work reported that this strategy achieved multisystem biochemical correction and neurological benefit in MPS II models, and the University of Manchester opened a combined phase 1/2 study for up to five infants with severe MPS II. Clinically viable hematopoietic stem-cell gene therapy Manchester MPS II stem-cell gene-therapy trial

Researchers are also pursuing direct gene editing. A 2026 mouse study used two AAV vectors carrying CRISPR/Cas9 components to insert a functional IDS sequence through homology-independent targeted integration, reporting biochemical and disease-related improvements in an MPS II model. This remains preclinical. Earlier clinical zinc-finger-nuclease editing with SB-913 did not show evidence of successful genome editing in participants, underscoring the challenge of safely delivering editors at therapeutic levels in vivo. CRISPR/Cas9 gene integration in MPS II mice GeneReviews: Mucopolysaccharidosis Type II

A major non-curative breakthrough has been tividenofusp alfa, a fusion protein that attaches I2S to a transferrin-receptor-binding component so that enzyme can be transported across the blood-brain barrier. In its phase 1/2 study, the drug lowered cerebrospinal-fluid heparan sulfate substantially; the FDA reported a 91% average decrease at week 24 among 44 measured children. Its March 2026 accelerated approval establishes that brain delivery of replacement enzyme is clinically feasible, while its required confirmatory trial will determine whether the biomarker improvement translates into durable neurological benefit. Phase 1/2 tividenofusp alfa study FDA approval of Avlayah

Clinical Trials and Experimental Approaches

CAMPSIITE is a phase 1/2/3, multicenter, open-label study of NAVSUNLI/RGX-121 sponsored by REGENXBIO for boys aged four months to under five years with neuronopathic MPS II. The trial is listed as active but not recruiting. After the FDA issued a Complete Response Letter in February 2026, citing questions about phenotype definition, the external natural-history control, and the suitability of the surrogate endpoint, REGENXBIO announced on June 22, 2026 that the agency would consider a resubmission using existing longer-term data under accelerated approval and that no additional trial was required. CAMPSIITE trial record RGX-121 Complete Response Letter update NAVSUNLI regulatory update

Denali’s tividenofusp alfa phase 1/2 trial enrolled 47 pediatric participants and remains in long-term follow-up, with estimated completion in 2031. Although Avlayah is now available in the United States for a defined pediatric population, its approval was accelerated rather than full, and Denali is conducting a randomized confirmatory study. The Manchester autologous stem-cell gene-therapy study is a small, single-arm phase 1/2 trial intended primarily to establish safety, enzyme activity, and early clinical effects in infants before developmental decline. Tividenofusp alfa trial record FDA approval of Avlayah Manchester MPS II stem-cell gene-therapy trial

Methodologies and Scientific Approaches

MPS II cure research relies on Ids-knockout mice, patient-derived cells, and non-human primates to compare enzyme production, GAG clearance, tissue pathology, immune responses, and neurobehavioral outcomes. These models are essential but imperfect: a liver-directed AAV8 approach normalized GAG storage in multiple body tissues in mice, yet showed no measurable central-nervous-system enzyme exposure in non-human primates, illustrating why apparent success in rodents may not translate to people. AAV gene therapy in rodents and non-human primates

Delivery technology is the central scientific problem. Programs use AAV vectors to add IDS directly in vivo, lentiviral vectors to engineer autologous stem cells ex vivo, receptor-mediated transport to carry infused enzyme into the brain, and experimental CRISPR systems to permanently insert corrective DNA. Trials increasingly measure heparan sulfate, especially the D2S6 disaccharide in cerebrospinal fluid, alongside enzyme activity, urinary GAGs, developmental testing, imaging, and caregiver-reported outcomes. CAMPSIITE 12-month data FDA approval of Avlayah

Leading Institutions and Funding

REGENXBIO, with commercial partner Nippon Shinyaku/NS Pharma, leads the most advanced one-time AAV gene-therapy program. Denali Therapeutics developed tividenofusp alfa and is running its long-term and confirmatory clinical program. The University of Manchester, Royal Manchester Children’s Hospital, Saint Mary’s Hospital, and Manchester University NHS Foundation Trust lead the infant autologous stem-cell gene-therapy study. NAVSUNLI regulatory update Manchester MPS II stem-cell gene-therapy trial

Public and patient-advocacy infrastructure also matters because intervention is likely to work best before neurological injury begins. In the United States, MPS II was added to the federal Recommended Uniform Screening Panel in 2022, creating a pathway for earlier identification where states implement screening. Regulatory incentives supporting development include orphan-drug, rare-pediatric-disease, fast-track, breakthrough-therapy, and regenerative-medicine designations across leading programs. HRSA Recommended Uniform Screening Panel FDA approval of Avlayah CAMPSIITE 12-month data

Strengths, Limitations, and Challenges

The strongest recent progress is the convergence of therapies that can address neurological disease: a brain-penetrant enzyme is now approved, a CNS-directed gene therapy has late-stage biomarker and developmental data, and an ex vivo stem-cell strategy could provide continuous enzyme production. The disease is particularly suitable for enzyme-restoration approaches because cross-correction means not every cell necessarily needs to be genetically repaired. FDA approval of Avlayah CAMPSIITE 12-month data Manchester MPS II stem-cell gene-therapy trial

However, substantial uncertainty remains. Biomarker reductions are promising but do not by themselves prove preserved cognition, skeletal health, or lifelong survival. Small trials, disease heterogeneity, and reliance on external natural-history comparisons make definitive efficacy assessment difficult. Safety is also central: in January 2026, the FDA placed RGX-121 on clinical hold after a brain tumor in a participant receiving the related MPS I program RGX-111 was found to contain an AAV integration event associated with a proto-oncogene; this did not establish that RGX-121 caused a tumor, but it highlighted the need for long-term surveillance of AAV gene therapies. RGX-121 Complete Response Letter update REGENXBIO MPS-program regulatory update

Outlook and Future Directions

As of August 8, 2026, Hunter syndrome is not curable, but the field has moved from treating body symptoms alone toward therapies designed to prevent or durably modify brain disease. The most important near-term milestones are the NAVSUNLI regulatory resubmission and any subsequent approval decision, publication of longer-term developmental and safety outcomes from CAMPSIITE, confirmatory clinical results for tividenofusp alfa, and first human safety and efficacy results from the Manchester stem-cell gene-therapy trial. A genuine cure will require convincing long-term evidence that early treatment safely preserves neurodevelopment while also preventing systemic disease across a lifetime. NAVSUNLI regulatory update FDA approval of Avlayah

References

Don't see your disease? Request a report